drugset / Trial / NCT02193217

A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303

NCT02193217

Phase 1 Completed 81 enrolled Tanabe Pharma Corporation

Summary

The purpose of this study is to explore the cardiac pharmacodynamics, safety and tolerability of MT-1303 in healthy subjects.

Timeline

Start
Primary completion
2014-12
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fingolimod Small molecule
Subject amiselimod Small molecule